Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Mesothelioma, Malignant 2Melanoma 2Carcinoma 2Adult Solid Neoplasm 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Solid Neoplasm 1Seminoma 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteolysis 1Neoplasm Metastasis 1Multiple Myeloma 1Malignant Solid Tumour 1Liver Neoplasms 1Hypercalcemia 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 6Lenalidomide 4pomalidomide 3isatuximab 3Kidney Transplantation 3Calcium Dobesilate 3glucarpidase 2Thalidomide 2Paclitaxel 2Gemcitabine 2Carboplatin 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1gamma-Glutamyl Hydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Renal Insufficiency × ARQ 197 × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡